DACLATASVIR (BMS-790052), AN NS5A REPLICATION COMPLEX INHIBITOR, COMBINED WITH PEGINTERFERON-ALFA-2a AND RIBAVIRIN IN TREATMENT-NAìVE HCV GENOTYPE 1 OR 4 SUBJECTS: PHASE 2B AI444010 STUDY INTERIM WEEK 24 RESULTS

Conference Reports for NATAP

Presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL)
Taipei, Taiwan
February 16-19, 2012


DACLATASVIR (BMS-790052), AN NS5A REPLICATION COMPLEX INHIBITOR, COMBINED WITH PEGINTERFERON-ALFA-2a AND RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1 OR 4 SUBJECTS: PHASE 2B AI444010 STUDY INTERIM WEEK 24 RESULTS

	Reported by Jules Levin 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012), Taipei International Convention Center, February 16-19, 2012 HEZODE C,1 HIRSCHFIELD GM,2 GHESQUIERE W,3 SIEVERT W,4 RODRIGUEZ-TORRES M,5 SHAFRAN S,6 THULUVATH PJ,7 YIN PD,8 DIVA U,8 SCHNITTMAN S8 1CHU HENRI MONDOR, CRETEIL, FRANCE; 2TORONTO WESTERN HOSPITAL, TORONTO, CANADA; 3PERCURO CLINICAL RESEARCH, LTD., VICTORIA, CANADA; 4MONASH MEDICAL CENTER, CLAYTON, VICTORIA, AUSTRALIA; 5FUNDACION DE INVESTIGACION DE DIEGO, SAN JUAN, PUERTO RICO; 6UNIVERSITY OF ALBERTA HOSPITAL, EDMONTON, CANADA, 7MERCY MEDICAL CENTER, BALTIMORE, MD, USA; 8BRISTOL-MYERS SQUIBB, WALLINGFORD, CT, USA